The resolution — proposed by six state medical societies — argues direct-to-consumer ads encourage patients to pressure their physicians into prescribing newer, more expensive medications. AMA’s policymaking body — the House of Delegates — will vote on the resolution during the association’s annual meeting in Chicago next week, according to STAT.
“[I]n a free enterprise system such as we have in the United States, the purchasing public should be educated,” the AMA resolution reads. “[A]dvertising should be required to state the manufacturer’s suggested retail price of those drugs.”
In 2015, AMA unsuccessfully attempted to convince lawmakers to institute a ban on direct-to-consumer advertising for prescription drugs all together.
More articles on supply chain:
AstraZeneca divests migraine drug for $302M
Advocacy group calls for FDA action on Bayer’s birth control device
Walmart pledges to slash supply chain greenhouse gas emission by 1B tons
